Prothena Corp. Public Ltd. Co.

PRTA

Nasdaq; healthcare; SIC 2834, Pharmaceutical Preparations; CIK 0001559053


None

No letter

6 of 14 inputs computable; 7 are required, with a score in every sleeve


Scoreboard	
Reliability	0.87 AUC filers with $120M to $591M assets; 95% interval 0.83 to 0.90; 206 events, 2020 to 2025
Peer failure rate	1.03% a year Item 1.03 bankruptcies, same asset band, 2012 to 2025
Size band	$120M to $591M assets total assets $326.8M
Standard universe	inside revenue above $1M and assets above $10M
Warnings	thin data not computable: distress, fortress balance sheet
Inputs computable	6 of 14
Graded from	filings received through Feb 27, 2026 252 days before the rescan; latest periodic filing 10-Q received Nov 5, 2026
Last close	$7.90 2026-11-05; market equity $405.7M; no price enters the letter

Share price, twelve months to the rescan



Split-adjusted close. Each lollipop is a rescan and carries the letter held then.

Letter at every rescan, 2012 to 2026



Sector percentile at each rescan, stronger toward the top; facts filed by each date only.

Business, in the company's words

opening of Item 1 of the 10-K received Feb 27, 2026

Prothena Corporation plc ("Prothena" or the "Company") is a late-stage clinical biotechnology company with expertise in protein dysregulation with the potential to change the course of devastating neurodegenerative and rare peripheral amyloid diseases. Fueled by its deep scientific expertise built over decades of research, the Company is advancing a pipeline of therapeutic candidates for a number of indications and novel targets for which its ability to integrate scientific insights around neurological dysfunction and the biology of misfolded proteins can be leveraged.

The fourteen inputs

lower percentile is stronger; sleeves and inputs within a sleeve carry equal weight

Input	Value	Peer median	Percentile, 0 to 100	Pct	Peers	Period end
Profitability, sleeve percentile 23.7						
Gross profitability	not computable	32.3%				
one or more required annual facts are missing						
Return on invested capital	not computable	9.3%				

Not investment advice. Informational and educational only. Data from SEC EDGAR, may contain errors, is not warranted. The grade ranks reported financial condition and is not a return forecast.

one or more required annual facts are missing					
Accruals ratio	(18.4%)	(6.6%)	23.7	802	2025-12-31
Gross margin stability, five years	not computable	2.8 pts			
five annual gross margins are required; found 0					
Solvency, sleeve percentile 39.1					
Twelve-month failure probability	not computable	0.07%			
latest liabilities, cash plus short-term investments, book equity, and shares are required					
Altman Z double-prime	(5.98)	(0.37)	54.6	747	2025-12-31
Net debt to EBITDA	not computable	1.82x			
one or more required annual facts are missing					
Interest coverage	not computable	(4.51x)			
one or more required annual facts are missing					
Current ratio	7.72x	2.94x	23.7	828	2025-12-31
Growth and financing, sleeve percentile 65.5					
Revenue growth, three-year compound	(43.6%)	10.0%	94.9	412	2025-12-31
Free cash flow growth, three-year compound	not computable	10.9%			
four consecutive annual FCF observations are required; found 0					
Reinvestment rate	not computable	37.1%			
one or more required annual facts are missing					
Asset growth, three years	(24.5%)	2.2%	88.5	696	2025-12-31
Net share issuance, one year	0.01%	2.5%	13.2	630	2026-02-20

Warnings

1 of 7 checks triggered; none of them enters the letter

Check	Measured
Thin data	6 of 14 grade factors are computable; minimum is 7

What the price implies

at the 2026-11-05 close; none of these enters the grade

Measure	Value	Peer median	Percentile
Twelve-month price change, skipping the latest month	(22.0%)	(2.1%)	36
Distance from 52-week high	(31.5%)	(30.4%)	49
EBIT to enterprise value	not computable	(1.5%)	
Free cash flow yield	not computable	(1.0%)	
Book value to price	0.66	0.29	76
Sales to price	0.02	0.30	9
Composite equity issuance, five years	25.0%	21.4%	52
Relative strength against the sector, log excess return	(0.42)	(0.19)	36

Diagnostics

shown on every report; none enters the grade

Measure	Value
Piotroski F-score None of 9, period end 2025-12-31	
Return on assets above zero	fail
Operating cash flow above zero	fail
Return on assets improved	fail
Operating cash flow exceeds net income	pass
Long-term leverage fell	fail
Current ratio improved	fail
No new shares issued	fail
Gross margin improved	fail
Asset turnover improved	fail

Not investment advice. Informational and educational only. Data from SEC EDGAR, may contain errors, is not warranted. The grade ranks reported financial condition and is not a return forecast.

Cash, filings, liquidity	
Cash and equivalents	$271.4M
Operating cash flow, four quarters	-$31.4M
Months of runway	103.6
Days since last periodic filing	1 (10-Q received Nov 5, 2026)
Median daily dollar volume, 63 sessions	$3.5M

Sources

every fact behind the inputs; each row links to its filing index on sec.gov

#	Concept	XBRL tag	Value	Period end	Received	Form	Accession
1	net income	us-gaap:NetIncomeLoss	-$244.1M	2025-12-31	2026-02-27	10-K	26-000008
2	operating cash flow	us-gaap:NetCashProvidedByUsedInOperatingActivities	-$163.6M	2025-12-31	2026-02-27	10-K	26-000008
3	assets	us-gaap:Assets	$326.8M	2025-12-31	2026-02-27	10-K	26-000008
4	assets	us-gaap:Assets	$547.1M	2024-12-31	2026-02-27	10-K	26-000008
5	current assets	us-gaap:AssetsCurrent	$315.2M	2025-12-31	2026-02-27	10-K	26-000008
6	current liabilities	us-gaap:LiabilitiesCurrent	$40.8M	2025-12-31	2026-02-27	10-K	26-000008
7	retained earnings	us-gaap:RetainedEarningsAccumulatedDeficit	-$1.3B	2025-12-31	2026-02-27	10-K	26-000008
8	operating income	us-gaap:OperatingIncomeLoss	-$214.6M	2025-12-31	2026-02-27	10-K	26-000008
9	book equity	us-gaap:StockholdersEquity	$280.5M	2025-12-31	2026-02-27	10-K	26-000008
10	liabilities	us-gaap:Liabilities	$46.3M	2025-12-31	2026-02-27	10-K	26-000008
11	revenue	us-gaap:RevenueFromContractWithCustomerExcludingA...	$9.7M	2025-12-31	2026-02-27	10-K	26-000008
12	revenue	us-gaap:RevenueFromContractWithCustomerExcludingA...	$135.2M	2024-12-31	2026-02-27	10-K	26-000008
13	revenue	us-gaap:RevenueFromContractWithCustomerExcludingA...	$91.4M	2023-12-31	2026-02-27	10-K	26-000008
14	revenue	us-gaap:RevenueFromContractWithCustomerExcludingA...	$53.9M	2022-12-31	2025-02-27	10-K	25-000009
15	assets	us-gaap:Assets	$696.4M	2023-12-31	2025-02-27	10-K	25-000009
16	assets	us-gaap:Assets	$758.0M	2022-12-31	2024-02-22	10-K	24-000008
17	shares outstanding	dei:EntityCommonStockSharesOutstanding	53,832,982	2026-02-20	2026-02-27	10-K	26-000008
18	shares outstanding	dei:EntityCommonStockSharesOutstanding	53,826,982	2025-02-20	2025-02-27	10-K	25-000009

Not investment advice. Informational and educational only. Data from SEC EDGAR, may contain errors, is not warranted. The grade ranks reported financial condition and is not a return forecast.